Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure
Arancha Martí-Martínez, Julio Núñez, Herminio López-Escribano, Rafael de la Espriella, Enrique Santas, Enrique Rodriguez-Borja, Òscar Miró, Pere Llorens, Aitor Alquézar-Arbé, Pablo Herrero-Puente · 2026
Read Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure by Arancha Martí-Martínez, Julio Núñez, Herminio López-Escribano, Rafael de la Espriella, Enrique Santas, Enrique Rodriguez-Borja, Òscar Miró, Pere Llorens, Aitor Alquézar-Arbé, Pablo Herrero-Puente (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13604260.txt.
Description
Arancha Martí-Martínez and co-authors link a hormone, fibroblast growth factor 23, to outcomes in acute heart failure, in this 2026 Europe PMC paper. The factor is emerging as a marker of fibrosis, a process tied to worsening heart failure. The team drew on a Spanish emergency department registry of more than six hundred patients with worsening disease.
Blood levels were measured at arrival. Over roughly a year of follow-up, about a third of patients died and over half hit the combined endpoint of death or another emergency visit. Event rates climbed steadily with the hormone's level, and each doubling of it raised risk for death and repeat events even after adjustment. The link held across patient subgroups.
Catalog record
| CREATOR | Arancha Martí-Martínez, Julio Núñez, Herminio López-Escribano, Rafael de la Espriella, Enrique Santas, Enrique Rodriguez-Borja, Òscar Miró, Pere Llorens, Aitor Alquézar-Arbé, Pablo Herrero-Puente |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |